Mainstream and fast-track genetic testing in pancreatic cancer patients and its impact on treatment: our experience in a tertiary hospital in Spain.
Genetic testing catches cancer-causing mutations in pancreatic cancer patients who don't meet family history criteria, potentially opening treatment options.
Mainstream germline testing in 223 pancreatic cancer patients found 14.3% pathogenic variant rate; 50% of PV carriers did not meet family history criteria; actionable mutations in 43.7% of PV carriers (BRCA2, PALB2, ATM) led to treatment modifications in 3% of all patients. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Retrospective observational cohort (n=223 patients, 5-year real-world experience 2019-2024)
- Category
- precision_oncology
- Maturity
- Validated
- Journal
- Familial Cancer
Why it surfaced
Precision oncology impact for high-unmet-need pancreatic cancer; demonstrates actionable variants missed by standard family-history criteria; directly informs PARP inhibitor and platinum-based therapy eligibility.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.